Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

114.78 +1.42 (+1.25%)
Streaming Delayed Price Updated: 1:23 PM EDT, Jul 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
News headline image
Incyte’s Q1 Earnings Call: Our Top 5 Analyst Questions
Incyte’s first quarter results were shaped by strong demand across its commercial portfolio, with growth supported by both new and existing products in hemat... 
Via StockStory
Topics Earnings
News headline image
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
From Incyte
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
News headline image
INCY Q1 Deep Dive: Pipeline Advances Offset Cautious Full-Year Guidance
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 20.9% year on year to $1.27 bi... 
Via StockStory
Incyte (NASDAQ:INCY) Beats Q1 Estimates and Unveils Robust Pipeline Catalysts ↗
Via Chartmill
Incyte Corp. (NASDAQ:INCY) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
Incyte (INCY) Q1 2026 Earnings Call Transcript ↗
Incyte (INCY) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Incyte (INCY) Q2 2025 Earnings Transcript ↗
Incyte (INCY) Q2 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Incyte (NASDAQ:INCY) Exceeds Q1 CY2026 Expectations
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 20.9% year on... 
Via StockStory
News headline image
Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates
From Incyte
Via Business Wire
News headline image
Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer
From Incyte
Via Business Wire
News headline image
Incyte Earnings: What To Look For From INCY
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results this Tuesday before the bell. Here’s what to look for. Incyte beat analy... 
Via StockStory
Topics Artificial Intelligence
News headline image
Incyte (INCY) Q4 2024 Earnings Transcript ↗
Incyte (INCY) Q4 2024 Earnings Transcript 
Via The Motley Fool
News headline image
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
From Incyte
Via Business Wire
News headline image
INCYTE CORP (NASDAQ:INCY) Presents a High-Growth Momentum Breakout Setup ↗
Incyte Corp (INCY) shows strong earnings growth and a positive technical setup, suggesting a potential breakout for momentum investors. 
Via Chartmill
News headline image
Incyte to Report First Quarter Financial Results
From Incyte
Via Business Wire
News headline image
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
From Adagene Inc.
Via GlobeNewswire
News headline image
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
Looking back on biotechnology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Incyte (NASDAQ:INCY) and its peers. The bio... 
Via StockStory
Topics Artificial Intelligence
News headline image
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
From Incyte
Via Business Wire
News headline image
Incyte Announces Executive Leadership Appointments
From Incyte
Via Business Wire
News headline image
2 Growth Stocks with Explosive Upside and 1 We Avoid
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va... 
Via StockStory
News headline image
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
From Incyte
Via Business Wire
News headline image
1 Cash-Heavy Stock to Target This Week and 2 Facing Headwinds
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg... 
Via StockStory
News headline image
2 Value Stocks to Consider Right Now and 1 We Ignore
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the... 
Via StockStory
News headline image
Incyte (INCY): Buy, Sell, or Hold Post Q4 Earnings?
Over the past six months, Incyte has been a great trade, beating the S&P 500 by 8.1%. Its stock price has climbed to $95.88, representing a healthy 11.3% inc... 
Via StockStory
Topics Stocks
News headline image
Incyte’s Drug Approved In Europe For Treating Yet Another Rare Cancer ↗
The company said that EC approved Zynyz in combination with carboplatin and paclitaxel for adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal... 
Via Stocktwits
News headline image
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
From Incyte
Via Business Wire
News headline image
1 Cash-Producing Stock with Exciting Potential and 2 We Avoid
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
News headline image
3 S&P 500 Stocks to Target This Week
The S&P 500 (^GSPC) is full of established businesses, but only some continue to outperform the market. A few standout companies are thriving thanks to strong fundamentals and sustained competitive... 
Via StockStory
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.